高敏C反应蛋白水平的变化与ACEI/D基因多态性的相关性分析

南方医科大学学报 ›› 2005, Vol. 25 ›› Issue (06): 691-695.

高敏C反应蛋白水平的变化与ACEI/D基因多态性的相关性分析

王玲, 周颖玲, 林曙光

广东省心血管病研究所, 广东, 广州, 510100

出版日期:2005-06-20 发布日期:2005-06-20
基金资助:
收稿日期:2005-3-28。
基金项目:广东省自然科学基金(033192)
作者简介:王玲(1970- ),女,主治医师,在读博士研究生,E-mail:doctorwangling@21cn.com

Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril

WANG Ling, ZHOU Ying-ling, LIN Shu-guang

广东省心血管病研究所, 广东, 广州, 510100

Online:2005-06-20 Published:2005-06-20

摘要/Abstract

摘要： 目的分析血管紧张素转换酶(ACE)(I/D)基因多态性与雷米普利治疗2型糖尿病合并动脉粥样硬化(AS)患者高敏C-反应蛋白(hsCRP)水平变化的相关性。方法病例选择:选择2型糖尿病合并颈动脉AS患者,排除明显影响肾素-血管紧张素-醛固酮系统的疾病、严重感染或肝肾疾病、恶性肿瘤、影响随访、半年内有1个月以上血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)用药史以及对ACEI过敏患者。样本量估计及分组:随机将患者分为ACEI组(雷米普利5mg,治疗组)99例和对照组(不用ACEI和ARB治疗)21例,其中ACEI组按ACE(I/D)基因型分为DD、ID、II组,每组保证最少20例。药物治疗方案:雷米普利2.5mg开始逐渐加至5mg,疗程至少3个月。收集所有患者心血管危险因素和相关指标作为基线指标。PCR检测ACE(I/D)单核苷酸多态性的频率。ELISA法定量检测治疗前后入选患者hsCRP水平的变化。随访3个月。协方差分析ACE基因DD、ID、II三种基因型患者治疗后hsCRP水平。结果与结论 雷米普利5mg治疗2型糖尿病合并AS患者3个月可降低患者hsCRP水平,按ACE(I/D)基因型分型DD、ID、II三组患者之间治疗后hsCRP水平无显著差异。

Abstract: Objective To explore the relationship between angiotensin converting enzyme (ACE) (I/D) gene polymorphism and the level of high-sensitivity C-reactive protein (hsCRP) in type 2 diabetic patients with atherosclerosis treated with ramipril. Methods A total of 118 in type 2 diabetic patients with atherosclerosis aged 35 years or older without clinical proteinuria, heart failure, or low ejection fraction (<40%), who were not taking ACE inhibitors or (ARB), were randomized into two groups to receive treatment with ramipril (ACEI group, beginning with 2.5 mg/d till reaching 5 mg/d) or placebo for 3 months. The 99 patients in ACEI group were further divided into 3 subgroups according to ACE (I/D) genotypes DD, ID and II, each group consisting of at least 20 patients. The level of hsCRP was detected by enzyme-linked immunosorbent assay before and after the therapy. Result and Conclusion After therapy, hsCRP level significantly decreased, but hsCRP levels showed no significant differences between the groups of different ACE genotypes.

中图分类号:

王玲, 周颖玲, 林曙光. 高敏C反应蛋白水平的变化与ACEI/D基因多态性的相关性分析[J]. 南方医科大学学报, 2005, 25(06): 691-695.

WANG Ling, ZHOU Ying-ling, LIN Shu-guang. Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril[J]. Journal of Southern Medical University, 2005, 25(06): 691-695.

参考文献

[1] (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy Heart Outcomes Prevention Evaluation [J]. Lancet, 2000, 355:253-8.
[2] Anderson JL, Carlquist JF, Home BD, et al. Cardiovascular pharmacoge-nomics:current status, future prospects [J]. J Cardiovasc Pharmacol Ther, 2003, 8(1):71-83.
[3] Mcnamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensinconverting enzyme deletion polymorphism in patients with congestive heart failure[J]. Circulation, 2001, 103(12):1608-10.
[4] Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response[J]. Clin Chem Lab Med, 2000, 38(9):853-6.
[5] Tetickovic E, Gajsek-Marchetti M, Matela J, et al. Three dimensional ultra-songraphy for the evaluation of atherosclerotic stenosis of the carotid trunk[J]. Coll Antropol, 2001, 25(2):511-20.
[6] Crouse JR, Harpold GH, Kahl FR, et al. Evaluation of scoring system for extracanial carotid atherosclerosis extent with B-mode ultrasound[J]. Stroke, 1986, 17(3):270-4.
[7] Harry Y, Rifai N. High sensitivity C-reactive protein and atherosclerosis:from theory to therapy [J]. Clin Biochem, 2000, 33 (8):601-10.
[8] Ikonom idis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in. patients with chronic stable angina and their reduction by aspirin [J]. Circulation, 1999, 100(8):793-8.
[9] Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastationt on plasma concentntion of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators [J].Circulation, 1999, 100(3):230-5.
[10] Libby P, Ridker PM. Inflammation and atherosclerosis:role of Creactive protein risk assessment [J]. Am J Med, 2004, 116(Suppl6A):95-165.
[11] Labarrere CA, Zaloga GP. C-reactive protein:from innocent bystander to pivotal mediator of atherosclerosis [J]. Am J Med, 2004,117:499-507.
[12] Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20):1557-65.
[13] Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease[J]. J Am Coll Cardiol, 2004, 44(2):362-8.
[14] 李宏芬,沈志霞,常延河,等.中国人群血管紧张素转换酶基因与血管紧张素Ⅱ-Ⅰ型受体基因A1166-C单核苷酸多态性分析[J].中华检验医学杂志,2003,26(2):89-92.Li HF, Shen ZX, Chang YH, et al. Distribution of polymorphism of angiotensin converting enzyme gene and A1 16-C single nucleotide polymorphism of angiotensin Ⅱ type Ⅰ receptor gene in normal Chinese [J]. Chin J Lab Med, 2003, 26(2):89-92.
[15] Evans WE, Relling MV. Pharmacogenomics:translating functional genomics into rational therapeutics[J]]. Science, 1999, 286(5439):487-91.
[16] Prasad A, Narayanan S, Husain S, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition [J]. Circulation, 2000, 102(1):35-41.
[17] Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin Ⅰ-coverting enzyme (ACE) gene controls plasma ACE levels [J].Am J Hum Genet, 1992, 51(1):197-205.